Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 4

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
es  stockholders’equity Balance as of December 31, 2023  17,667,663  $17,191,315  $(5,011,891) $(1,844,278) $(677,294) $9,657,852 Net loss for the period  -   -   -   (103,757)  -   (103,757)Foreign currency translation loss  -   -   -   -   (209,908)  (209,908)Balance as of March 31, 2024  17,667,663  $17,191,315  $(5,011,891) $(1,948,035) $(887,202) $9,344,187 

Share activity (number of shares or both number and amount of shares) has been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 12.

  Common stock  Additional    Accumulated other  Total   Number of shares  Amount  paid incapital  Accumulated deficit  comprehensivelosses  stockholders’equity Balance as of December 31, 2024  17,967,663  $17,332,315  $(5,011,891) $(3,442,620) $(555,000) $8,322,804 Net loss for the period  -   -   -   (623,327)  -   (623,327)Foreign currency translation gain  -   -   -   -   72,159   72,159 Balance as of March 31, 2025  17,967,663  $17,332,315  $(5,011,891) $(4,065,947) $(482,841) $7,771,636 

See accompanying notes to the condensed consolidated financial statements.

 7Table of Contents

BIONEXUS GENE LAB CORP. 

CONSOLIDATED STATEMENTS OF CASH FLOWS 

FOR THE THREE MONTHS ENDED MARCH 31,